CN102460153A - 监控神经精神疾病治疗的生物标记 - Google Patents
监控神经精神疾病治疗的生物标记 Download PDFInfo
- Publication number
- CN102460153A CN102460153A CN2010800258668A CN201080025866A CN102460153A CN 102460153 A CN102460153 A CN 102460153A CN 2010800258668 A CN2010800258668 A CN 2010800258668A CN 201080025866 A CN201080025866 A CN 201080025866A CN 102460153 A CN102460153 A CN 102460153A
- Authority
- CN
- China
- Prior art keywords
- treatment
- biomarker
- kinds
- biological sample
- vagal stimulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 130
- 238000011282 treatment Methods 0.000 title claims abstract description 108
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 85
- 201000010099 disease Diseases 0.000 title claims abstract description 83
- 238000012544 monitoring process Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 109
- 239000012472 biological sample Substances 0.000 claims description 52
- 230000000638 stimulation Effects 0.000 claims description 46
- 206010061218 Inflammation Diseases 0.000 claims description 42
- 230000004054 inflammatory process Effects 0.000 claims description 42
- 230000001515 vagal effect Effects 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 27
- 239000012491 analyte Substances 0.000 claims description 22
- 238000011156 evaluation Methods 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 15
- 230000002503 metabolic effect Effects 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 10
- 230000004797 therapeutic response Effects 0.000 claims description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
- 238000003384 imaging method Methods 0.000 claims description 6
- 208000020401 Depressive disease Diseases 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000009225 cognitive behavioral therapy Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000002651 drug therapy Methods 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 230000000508 neurotrophic effect Effects 0.000 claims description 4
- 238000001671 psychotherapy Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 abstract description 13
- 230000004044 response Effects 0.000 abstract description 5
- 210000001186 vagus nerve Anatomy 0.000 abstract description 5
- 230000007383 nerve stimulation Effects 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 description 49
- 208000011736 mal de Debarquement Diseases 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 230000036541 health Effects 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- 230000000857 drug effect Effects 0.000 description 18
- 238000011160 research Methods 0.000 description 18
- 230000000994 depressogenic effect Effects 0.000 description 17
- 230000004060 metabolic process Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000003745 diagnosis Methods 0.000 description 16
- 238000004422 calculation algorithm Methods 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 108010025020 Nerve Growth Factor Proteins 0.000 description 11
- 102000007072 Nerve Growth Factors Human genes 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 10
- 229940054157 lexapro Drugs 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 239000003900 neurotrophic factor Substances 0.000 description 9
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000004590 computer program Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000003815 Interleukin-11 Human genes 0.000 description 6
- 108090000177 Interleukin-11 Proteins 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 229940074383 interleukin-11 Drugs 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000002969 morbid Effects 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
- 102000003946 Prolactin Human genes 0.000 description 4
- 108010057464 Prolactin Proteins 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 238000007620 mathematical function Methods 0.000 description 4
- 230000005055 memory storage Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 102000003810 Interleukin-18 Human genes 0.000 description 3
- 108090000171 Interleukin-18 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102100029268 Neurotrophin-3 Human genes 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000005424 photoluminescence Methods 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
- 102100026376 Artemin Human genes 0.000 description 2
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 2
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091061482 Glial cell line-derived neurotrophic factor family Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102400000569 Myeloperoxidase Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 101800000933 Non-structural protein 10 Proteins 0.000 description 2
- 102100024735 Resistin Human genes 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002635 electroconvulsive therapy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000000865 membrane-inlet mass spectrometry Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 101710205806 Artemin Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 description 1
- 101000686909 Homo sapiens Resistin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102000043322 Reelin Human genes 0.000 description 1
- 108700038365 Reelin Proteins 0.000 description 1
- 101150057388 Reln gene Proteins 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 101710190759 Serum amyloid A protein Proteins 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Signal Processing (AREA)
- Immunology (AREA)
- Software Systems (AREA)
- Evolutionary Biology (AREA)
- Bioethics (AREA)
- Theoretical Computer Science (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Microbiology (AREA)
- Artificial Intelligence (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16698609P | 2009-04-06 | 2009-04-06 | |
| US61/166,986 | 2009-04-06 | ||
| PCT/US2010/030104 WO2010118035A2 (en) | 2009-04-06 | 2010-04-06 | Biomarkers for monitoring treatment of neuropsychiatric diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102460153A true CN102460153A (zh) | 2012-05-16 |
Family
ID=42936849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800258668A Pending CN102460153A (zh) | 2009-04-06 | 2010-04-06 | 监控神经精神疾病治疗的生物标记 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100280562A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2417448A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012523009A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102460153A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2757659A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010118035A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111524596A (zh) * | 2020-04-07 | 2020-08-11 | 上海市精神卫生中心（上海市心理咨询培训中心） | 一种判断青少年双相障碍发病风险的方法 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US8868177B2 (en) * | 2009-03-20 | 2014-10-21 | ElectroCore, LLC | Non-invasive treatment of neurodegenerative diseases |
| US8158374B1 (en) | 2006-09-05 | 2012-04-17 | Ridge Diagnostics, Inc. | Quantitative diagnostic methods using multiple parameters |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| EP2337866B1 (en) * | 2008-10-15 | 2014-07-30 | Ridge Diagnostics, Inc. | Human biomarker hypermapping for depressive disorders |
| WO2010059709A2 (en) | 2008-11-18 | 2010-05-27 | Ridge Diagnostics, Inc. | Metabolic syndrome and hpa axis biomarkers for major depressive disorder |
| CN102483398A (zh) * | 2009-04-01 | 2012-05-30 | 里奇诊断学股份有限公司 | 监控神经精神疾病治疗的生物标记 |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| WO2011079309A2 (en) | 2009-12-23 | 2011-06-30 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| EP2529222A4 (en) * | 2010-01-26 | 2013-10-09 | Ridge Diagnostics Inc | MULTIPLE BIOMARKER PANELS FOR STRATIFYING ILLNESS HEAVY GRADES AND MONITORING THE TREATMENT OF DEPRESSIONS |
| EP2653476B1 (en) * | 2010-12-16 | 2017-04-26 | National Institute of Advanced Industrial Science And Technology | Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases |
| US20120238837A1 (en) * | 2011-03-16 | 2012-09-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System, devices, and methods for real-time monitoring of cerebrospinal fluid for markers of progressive conditions |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| US8737709B2 (en) * | 2012-04-30 | 2014-05-27 | General Electric Company | Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue |
| EP3751283A3 (en) | 2013-07-11 | 2021-03-24 | University of North Texas Health Science Center at Fort Worth | Blood-based screen for detecting neurological diseases in primary care settings |
| EP3074525B1 (en) | 2013-11-26 | 2024-06-26 | University of North Texas Health Science Center at Fort Worth | Personalized medicine approach for treating cognitive loss |
| WO2015127476A1 (en) * | 2014-02-24 | 2015-08-27 | Setpoint Medial Corporation | Vagus nerve stimulation screening test |
| US20170161441A1 (en) * | 2014-07-02 | 2017-06-08 | Ridge Diagnostics, Inc. | Methods and materials for treating pain and depression |
| US11154712B2 (en) * | 2014-08-28 | 2021-10-26 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for assessing efficacy of renal neuromodulation and associated systems and devices |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| US10314501B2 (en) | 2016-01-20 | 2019-06-11 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| EP3518745A1 (en) | 2016-10-28 | 2019-08-07 | Telefonica Innovacion Alpha S.L | System and a method for enabling responsive cognitive behavioral therapy |
| WO2018195238A1 (en) * | 2017-04-20 | 2018-10-25 | The Feinstein Institute For Medical Research | Systems and methods for real-time monitoring of physiological biomarkers through nerve signals and uses thereof |
| EP3668402B1 (en) | 2017-08-14 | 2024-07-31 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| US10837970B2 (en) | 2017-09-01 | 2020-11-17 | Venn Biosciences Corporation | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring |
| CA3088512C (en) | 2018-01-18 | 2023-09-19 | University Of North Texas Health Science Center At Fort Worth | Companion diagnostic for nsaids and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| WO2020210786A1 (en) | 2019-04-12 | 2020-10-15 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| KR20230012585A (ko) | 2020-05-21 | 2023-01-26 | 더 파인스타인 인스티튜츠 포 메디칼 리서치 | 미주 신경 자극을 위한 시스템들 및 방법들 |
| WO2022245878A1 (en) | 2021-05-17 | 2022-11-24 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5359681A (en) * | 1993-01-11 | 1994-10-25 | University Of Washington | Fiber optic sensor and methods and apparatus relating thereto |
| US5882203A (en) * | 1995-05-31 | 1999-03-16 | Correa; Elsa I. | Method of detecting depression |
| US5658802A (en) * | 1995-09-07 | 1997-08-19 | Microfab Technologies, Inc. | Method and apparatus for making miniaturized diagnostic arrays |
| US5804453A (en) * | 1996-02-09 | 1998-09-08 | Duan-Jun Chen | Fiber optic direct-sensing bioprobe using a phase-tracking approach |
| US20050123938A1 (en) * | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| US20030032773A1 (en) * | 2000-02-24 | 2003-02-13 | Herath Herath Mudiyanselage Athula Chandrasiri | Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (BAD) and unipolar depression |
| AU4345001A (en) * | 2000-03-09 | 2001-09-17 | Clinical Analysis Corp | Medical diagnostic system |
| US7118710B2 (en) * | 2000-10-30 | 2006-10-10 | Sru Biosystems, Inc. | Label-free high-throughput optical technique for detecting biomolecular interactions |
| US6905816B2 (en) * | 2000-11-27 | 2005-06-14 | Intelligent Medical Devices, Inc. | Clinically intelligent diagnostic devices and methods |
| ATE458199T1 (de) * | 2001-05-04 | 2010-03-15 | Biosite Inc | Diagnostische marker der akuten koronaren syndrome und ihre verwendungen |
| US6710877B2 (en) * | 2001-07-23 | 2004-03-23 | Corning Incorporated | Apparatus and methods for determining biomolecular interactions |
| US20050095646A1 (en) * | 2001-11-19 | 2005-05-05 | Sherman Michael I. | Method of using a non-antibody protein to detect and measure an analyte |
| US7136518B2 (en) * | 2003-04-18 | 2006-11-14 | Medispectra, Inc. | Methods and apparatus for displaying diagnostic data |
| US20040152107A1 (en) * | 2002-09-18 | 2004-08-05 | C. Anthony Altar | Gene signature of electroshock therapy and methods of use |
| KR20040032451A (ko) * | 2002-10-09 | 2004-04-17 | 삼성전자주식회사 | 생체신호 기반의 건강 관리 기능을 갖는 모바일 기기 및이를 이용한 건강 관리 방법 |
| US7490085B2 (en) * | 2002-12-18 | 2009-02-10 | Ge Medical Systems Global Technology Company, Llc | Computer-assisted data processing system and method incorporating automated learning |
| US7418290B2 (en) * | 2003-05-06 | 2008-08-26 | Aspect Medical Systems, Inc. | System and method of assessment of the efficacy of treatment of neurological disorders using the electroencephalogram |
| US7706871B2 (en) * | 2003-05-06 | 2010-04-27 | Nellcor Puritan Bennett Llc | System and method of prediction of response to neurological treatment using the electroencephalogram |
| US20040228765A1 (en) * | 2003-05-14 | 2004-11-18 | Witty Thomas R. | Point of care diagnostic platform |
| US20040228766A1 (en) * | 2003-05-14 | 2004-11-18 | Witty Thomas R. | Point of care diagnostic platform |
| WO2005017203A2 (en) * | 2003-07-11 | 2005-02-24 | Yale University | Systems and methods for diagnosing and treating psychological and behavioral conditions |
| US20070092888A1 (en) * | 2003-09-23 | 2007-04-26 | Cornelius Diamond | Diagnostic markers of hypertension and methods of use thereof |
| US20050069936A1 (en) * | 2003-09-26 | 2005-03-31 | Cornelius Diamond | Diagnostic markers of depression treatment and methods of use thereof |
| US7394547B2 (en) * | 2003-11-06 | 2008-07-01 | Fortebio, Inc. | Fiber-optic assay apparatus based on phase-shift interferometry |
| JP2005312435A (ja) * | 2004-03-29 | 2005-11-10 | Kazuhito Rokutan | うつ病の評価方法 |
| US20050254065A1 (en) * | 2004-05-12 | 2005-11-17 | Stokowski Stanley E | Method and apparatus for detecting surface characteristics on a mask blank |
| AU2005257705A1 (en) * | 2004-06-24 | 2006-01-05 | Ge Healthcare Bio-Sciences Ab | Method for detecting molecular surface interactions |
| US20060063199A1 (en) * | 2004-09-21 | 2006-03-23 | Elgebaly Salwa A | Diagnostic marker |
| US7445887B2 (en) * | 2005-01-07 | 2008-11-04 | Fortebio, Inc. | Enzyme activity measurements using bio-layer interferometry |
| JP2007024822A (ja) * | 2005-07-21 | 2007-02-01 | Aska Pharmaceutical Co Ltd | 男性の更年期又はうつ病の鑑別方法 |
| AU2006303026A1 (en) * | 2005-10-18 | 2007-04-26 | Psynova Neurotech Limited | Methods and biomarkers for diagnosing and monitoring psychotic disorders such as schizophrenia |
| US20070161042A1 (en) * | 2006-01-11 | 2007-07-12 | Fortebio, Inc. | Methods for characterizing molecular interactions |
| CA2642706C (en) * | 2006-02-17 | 2017-08-01 | Atsuo Sekiyama | Biological load indicator and method of measuring biological load |
| US20080015465A1 (en) * | 2006-06-15 | 2008-01-17 | Scuderi Gaetano J | Methods for diagnosing and treating pain in the spinal cord |
| US7651836B2 (en) * | 2006-08-04 | 2010-01-26 | Hospital Santiago Apóstol | Methods for diagnosis and prognostic of psychiatric diseases |
| US8158374B1 (en) * | 2006-09-05 | 2012-04-17 | Ridge Diagnostics, Inc. | Quantitative diagnostic methods using multiple parameters |
| US20080199866A1 (en) * | 2006-10-10 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Snp detection and other methods for characterizing and treating bipolar disorder and other ailments |
| WO2008099972A1 (ja) * | 2007-02-16 | 2008-08-21 | Shimadzu Corporation | 上皮性卵巣癌の組織型識別マーカー、及びそれを用いた組織型に基づく上皮性卵巣癌の罹患の識別法 |
| US20080281531A1 (en) * | 2007-03-15 | 2008-11-13 | Kazuhito Rokutan | Method for Diagnosing Depression |
| EP2329260A4 (en) * | 2008-03-04 | 2011-08-03 | Ridge Diagnostics Inc | DIAGNOSIS AND MONITORING OF DEPRESSIVE DISORDERS BASED ON A PLURALITY OF BIOMARKER PANELS |
| JP5658571B2 (ja) * | 2008-03-12 | 2015-01-28 | リッジ ダイアグノスティックス，インコーポレイテッド | うつ障害をモニタリングするための炎症バイオマーカー |
| EP2337866B1 (en) * | 2008-10-15 | 2014-07-30 | Ridge Diagnostics, Inc. | Human biomarker hypermapping for depressive disorders |
| WO2010059709A2 (en) * | 2008-11-18 | 2010-05-27 | Ridge Diagnostics, Inc. | Metabolic syndrome and hpa axis biomarkers for major depressive disorder |
| CN102483398A (zh) * | 2009-04-01 | 2012-05-30 | 里奇诊断学股份有限公司 | 监控神经精神疾病治疗的生物标记 |
| EP2529222A4 (en) * | 2010-01-26 | 2013-10-09 | Ridge Diagnostics Inc | MULTIPLE BIOMARKER PANELS FOR STRATIFYING ILLNESS HEAVY GRADES AND MONITORING THE TREATMENT OF DEPRESSIONS |
| CN103370624A (zh) * | 2010-12-06 | 2013-10-23 | 里奇诊断学股份有限公司 | 监控神经精神疾病治疗的生物标记 |
-
2010
- 2010-04-06 CA CA2757659A patent/CA2757659A1/en not_active Abandoned
- 2010-04-06 WO PCT/US2010/030104 patent/WO2010118035A2/en not_active Ceased
- 2010-04-06 EP EP10762304A patent/EP2417448A4/en not_active Withdrawn
- 2010-04-06 JP JP2012504782A patent/JP2012523009A/ja active Pending
- 2010-04-06 CN CN2010800258668A patent/CN102460153A/zh active Pending
- 2010-04-06 US US12/754,770 patent/US20100280562A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111524596A (zh) * | 2020-04-07 | 2020-08-11 | 上海市精神卫生中心（上海市心理咨询培训中心） | 一种判断青少年双相障碍发病风险的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2417448A4 (en) | 2012-10-24 |
| WO2010118035A3 (en) | 2011-01-13 |
| CA2757659A1 (en) | 2010-10-14 |
| EP2417448A2 (en) | 2012-02-15 |
| JP2012523009A (ja) | 2012-09-27 |
| WO2010118035A2 (en) | 2010-10-14 |
| US20100280562A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102460153A (zh) | 监控神经精神疾病治疗的生物标记 | |
| JP5675771B2 (ja) | 精神神経疾患の治療をモニタリングするためのバイオマーカー | |
| JP5658571B2 (ja) | うつ障害をモニタリングするための炎症バイオマーカー | |
| JP5663314B2 (ja) | 多数のバイオマーカーパネルに基づくうつ障害の診断およびモニタリング | |
| JP5540000B2 (ja) | うつ病性障害のヒトバイオマーカーハイパーマッピング | |
| US20110213219A1 (en) | Multiple Biomarker Panels to Stratify Disease Severity and Monitor Treatment of Depression | |
| US20120178118A1 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| US20170131295A1 (en) | Multiple biomarker panels to stratify disease severity and monitor treatment of depression | |
| US20160342757A1 (en) | Diagnosing and monitoring depression disorders | |
| US20170161441A1 (en) | Methods and materials for treating pain and depression | |
| HK1171081A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1171807A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1190789A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1171081 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120516 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1171081 Country of ref document: HK |